Our Blog

 

Comparing the Effectiveness of Second-line Antidiabetic Medications on Cardiovascular Events in Patients with Type 2 Diabetes Mellitus

By Mary R Dicklin PhD Kevin Maki PhD | Dec 31, 2018 | 0 Comments

Comparing the Effectiveness of Second-line Antidiabetic Medications on Cardiovascular Events in Patients with Type 2 Diabetes Mellitus By Mary R Dicklin, PhD and Kevin C Maki, PhD, CLS, FNLA   Cardiovascular disease is the leading cause of morbidity and mortality among patients with type 2 diabetes (T2D).1  Metformin is widely recommended as first-line therapy, but

Read More

2018 American College of Cardiology/American Heart Association Cholesterol Clinical Practice Guidelines

By Heather Nelson Cortes PhD and Kevin C Maki PhD | Dec 3, 2018 | 0 Comments

2018 American College of Cardiology/American Heart Association Cholesterol Clinical Practice Guidelines 2018 American College of Cardiology/American Heart Association Cholesterol Clinical Practice Guidelines  By Heather Nelson Cortes, PhD, Mary R Dicklin, PhD and Kevin C Maki, PhD   The American College of Cardiology (ACC) and the American Heart Association (AHA) recently released their 2018 Guideline on

Read More

Summaries of Late-breaking Science Presentations at the 2018 American Heart Association meeting in Chicago, IL

By Heather Nelson Cortes PhD and Kevin C Maki PhD | Nov 30, 2018 | 0 Comments

Summaries of Late-breaking Science Presentations at the 2018 American Heart Association meeting in Chicago, IL Summaries of Late-breaking Science Presentations at the 2018 American Heart Association meeting in Chicago, IL  By Heather Nelson Cortes, PhD and Kevin C Maki, PhD  Dapagliflozin and Cardiovascular Events in the DECLARE-TIMI 58 Trial The Dapagliflozin Effect on Cardiovascular Events—Thrombolysis

Read More

More Recent Headlines from the Late-breaking Clinical Trial Presentations at the American Heart Association Scientific Sessions 2

By Kevin C Maki PhD and Mary R Dicklin PhD | Nov 29, 2018 | 0 Comments

More Recent Headlines from the Late-breaking Clinical Trial Presentations at the American Heart Association Scientific Sessions – Less Pessimism Called for When Interpreting the Results from VITAL Regarding Cardiovascular Benefits with Omega-3   By Kevin C Maki, PhD and Mary R Dicklin, PhD  The primary results from the Vitamin D and Omega-3 Trial (VITAL) were

Read More

Recent Headlines from the Late-breaking Clinical Trial Presentations at the American Heart Association Scientific Sessions

By Kevin C Maki PhD and Mary R Dicklin PhD | Nov 27, 2018 | 1 Comment

Recent Headlines from the Late-breaking Clinical Trial Presentations at the American Heart Association Scientific Sessions – REDUCE-IT – a Landmark Cardiovascular Outcomes Study of an Omega-3 Fatty Acid   By Kevin C Maki, PhD and Mary R Dicklin, PhD  The primary results from the Reduction of Cardiovascular Events with Eicosapentaenoic Acid (EPA) – Intervention Trial

Read More

Mechanisms Responsible for the Benefit on Cardiovascular Risk in the REDUCE-IT Trial

By Kevin Maki PhD | Oct 12, 2018 | 0 Comments

Mechanisms Responsible for the Benefit on Cardiovascular Risk in the REDUCE-IT Trial By Kevin C Maki, PhD   Recently, we learned of the impressive topline results from the Reduction of Cardiovascular Events with Eicosapentaenoic Acid (EPA) – Intervention Trial (REDUCE-IT), which showed that Vascepa® (icosapent ethyl or EPA ethyl esters) lowered major adverse cardiovascular events

Read More

Meta-regression Characterizes the Relationships Between Changes in Dietary Cholesterol Intake and Plasma Low-density and High-density Lipoprotein Cholesterol Changes

By Kevin Maki PhD | Oct 11, 2018 | 0 Comments

Meta-regression Characterizes the Relationships Between Changes in Dietary Cholesterol Intake and Plasma Low-density and High-density Lipoprotein Cholesterol Changes By Kevin C Maki, PhD and Orsolya M Palacios, PhD   Our group recently collaborated with scientists from the University of Cincinnati to conduct meta-regression analyses that investigated the dose-response relationships between changes in dietary cholesterol intake

Read More

Topline Results from REDUCE-IT Show a Significant Reduction in Cardiovascular Outcomes with Omega-3 Fatty Acid

By Kevin C Maki PhD and Mary R Dicklin PhD | Oct 11, 2018 | 0 Comments

Topline Results from REDUCE-IT Show a Significant Reduction in Cardiovascular Outcomes with Omega-3 Fatty Acid By Kevin C Maki, PhD and Mary R Dicklin, PhD   Exciting topline results from the Reduction of Cardiovascular Events with Eicosapentaenoic Acid (EPA) – Intervention Trial (REDUCE-IT) were recently announced by Amarin, the maker of Vascepa®.1 The full results

Read More

Results from A Study of Cardiovascular Events in Diabetes (ASCEND): Taking a Closer Look at the Potential Benefit of Omega-3 Fatty Acids for Preventing Cardiac Death

By Kevin C Maki PhD and Mary R Dicklin PhD | Sep 13, 2018 | 0 Comments

Results from A Study of Cardiovascular Events in Diabetes (ASCEND): Taking a Closer Look at the Potential Benefit of Omega-3 Fatty Acids for Preventing Cardiac Death By Kevin C Maki, PhD; Mary R Dicklin, PhD   Results from A Study of Cardiovascular Events in Diabetes (ASCEND) were recently presented at the European Society of Cardiology

Read More

A Review of Three Recently Published Papers on Dietary Approaches to Weight Loss and Fat Mobilization

By Kristen N Smith PhD RDN Mary R Dicklin PhD Kevin Maki PhD | May 24, 2018 | 0 Comments

A Review of Three Recently Published Papers on Dietary Approaches to Weight Loss and Fat Mobilization By Kristen N Smith, PhD, RD; Mary R Dicklin, PhD; Kevin C Maki, PhD, CLS   Background: There have been multiple papers published this year focusing on various dietary approaches for producing weight loss and their effects on weight-related

Read More